Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

Makoto Nishio, Shuji Murakami, Hisato Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma

Open source

DOI: 10.1158/2767-9764.crc-23-0313
Published: 2024-01-29
Container: Cancer Research Communications
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/2767-9764.crc-23-0313,
  title = {Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort},
  author = {Makoto Nishio and Shuji Murakami and Hisato Kawakami and Kyoichi Okishio and Motohiro Tamiya and Haruki Kobayashi and Daichi Fujimoto and Shunichi Sugawara and Toshiyuki Kozuki and Yuko Oya and Hiroki Izumi and Takayuki Shiroyama and Miyako Satouchi and Noboru Yamamoto and Shota Kaname and Daiko Matsuoka and Yohei Otake and Takao Takase and Taro Semba and Koichi Azuma},
  year = {2024},
  journal = {Cancer Research Communications},
  doi = {10.1158/2767-9764.crc-23-0313},
  url = {https://doi.org/10.1158/2767-9764.crc-23-0313}
}

RIS

TY  - JOUR
TI  - Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort
AU  - Makoto Nishio
AU  - Shuji Murakami
AU  - Hisato Kawakami
AU  - Kyoichi Okishio
AU  - Motohiro Tamiya
AU  - Haruki Kobayashi
AU  - Daichi Fujimoto
AU  - Shunichi Sugawara
AU  - Toshiyuki Kozuki
AU  - Yuko Oya
AU  - Hiroki Izumi
AU  - Takayuki Shiroyama
AU  - Miyako Satouchi
AU  - Noboru Yamamoto
AU  - Shota Kaname
AU  - Daiko Matsuoka
AU  - Yohei Otake
AU  - Takao Takase
AU  - Taro Semba
AU  - Koichi Azuma
PY  - 2024
JO  - Cancer Research Communications
DO  - 10.1158/2767-9764.crc-23-0313
UR  - https://doi.org/10.1158/2767-9764.crc-23-0313
ER  -

APA

Nishio, M., Murakami, S., Kawakami, H., Okishio, K., Tamiya, M., Kobayashi, H., Fujimoto, D., Sugawara, S., Kozuki, T., Oya, Y., Izumi, H., Shiroyama, T., Satouchi, M., Yamamoto, N., Kaname, S., Matsuoka, D., Otake, Y., Takase, T., Semba, T., & Azuma, K. (2024). Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-23-0313

Source records

crossref · retrieved 2026-09-26T14:36:40.883Z